Dr. Vikrant Sahasrabuddhe is Program Director in the Division of Cancer Prevention at the National Cancer Institute overseeing clinical trials focused on prevention of cervical cancer and other human papillomavirus (HPV)-related cancers. Dr. Sahasrabuddhe provides scientific direction and strategic guidance for efforts on optimization of clinic-based and population-based precision prevention strategies for HPV-related cancers and building the evidence base for their implementation in the United States and globally. These efforts include: (1) optimizing dosing and delivery of currently licensed HPV vaccines, and early phase evaluation of next generation lower-cost and higher-valency HPV vaccines; (2) evaluation of novel strategies for screening, triage, treatment of precancers, and prevention of post-treatment recurrences; (3) improving prevention strategies for HPV-related cancers in immunocompromised individuals including HIV-infected adults, perinatally-HIV-infected adolescents, and solid organ transplant recipients; and (4) expanding access to cancer prevention services globally via improved application of available scientific evidence.
Dr. Sahasrabuddhe received his medical degree from the University of Pune in India, his master's and doctorate degrees in public health from the University of Alabama at Birmingham, and completed fellowship training in epidemiology at the Johns Hopkins University Bloomberg School of Public Health and at the National Cancer Institute. Dr. Sahasrabuddhe served on the faculty at Vanderbilt University between 2005-2015, most recently as Research Associate Professor of Medicine. He has published widely across a broad spectrum of clinical, epidemiologic, and implementation research areas on infection-associated cancers with high or rising incidence and mortality burden.